Prurigo Nodularis Treatment Market Size, Share, and Trends 2024 to 2033

Prurigo Nodularis Treatment Market Size and Growth 2024 to 2033

The global prurigo nodularis treatment market size was valued at USD 2.13 billion in 2023 and is anticipated to reach around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033. The use of prurigo nodularis treatment helps to stop flattening skin lesions, and the itch-scratch cycle, and reduces systematic or topical therapies, skin scratching and irritation, and itchiness directly.

Prurigo Nodularis Treatment Market Key Takeaways

• The North America prurigo nodularis treatment market size accounted for USD 870 million in 2023 and is expected to attain around USD 1,300 million by 2033.
• North America dominated the market with the major market share of 41% in 2023.
• Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
• By product type, the corticosteroids segment has held the biggest market share of 37% in 2023.
• By product type, the antihistamines segment is estimated to be the fastest growing during the forecast period.
• By distribution channel type, the retail pharmacies segment has contributed more than 42% of market share in 2023.
• By distribution channel type, the online pharmacies segment is expected to be the fastest growing during the forecast period.

Prurigo Nodularis Treatment Market Size in the U.S. 2024 to 2033

The U.S. prurigo nodularis treatment market size reached USD 650 million in 2023 and is predicted to be worth around USD 980 million by 2033, at a CAGR of 4.19% from 2024 to 2033.

North America dominated the market in 2023. The increasing senior population leads to prurigo nodularis conditions and demand for prurigo nodularis treatment in the North American region. Particularly in the senior population, there is high prurigo nodularis seen. For the treatment of senior patients with serious prurigo nodularis, the Dupixent was authorized by Health Canada. These factors help to the growth of the prurigo nodularis treatment market in the North American Region.

• In September 2022, for the treatments of the senior population who suffer from prurigo nodularis a dupilumab or Dupixent injection was approved by the Food and Drug Administration. This Dupixent injection is also used for the treatment of eosinophilic esophagitis, nasal polyposis, chronic rhinosinusitis, asthma, and atopic dermatitis.
• In July 2023, Prurigo nodularis treatment is needed in the United States due to there being nearly 72 new prurigo nodularis patients for every 100000 people, and the age of the people is between 18 years and 64 years according to the prurigo nodularis trial.

Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033. India and China are the leading countries in the North American region for prurigo nodularis treatment. Prurigo nodularis may be higher in India, but there is a lack of published evidence. In India, there is an increase in dermatophytosis, which is a major cause of prurigo nodularis treatment. In India, prurigo nodularis homeopathy treatments are present. These factors help the growth of the prurigo nodularis treatment market in the Asia Pacific region.

• In November 2023, a biologic Dupixent of Sanofi for use in children aged six months to 5 years with serious atopic dermatitis was approved by China. For the treatment of adults in China who suffer from prurigo, nodularis condition was the first treatment approved by China.
• In April 2024, Incyte and CMS (China Medical System Holdings Ltd) announced the license agreement and collaboration for Povorcitinib in Southeast Asia and China. This is a selective oral JAK1 inhibitor Povorcitiinib, an investigational medicine that was discovered by Incyte and estimated for the treatment of prurigo nodularis, chronic spontaneous urticaria, asthma, hidradenitis suppurativa, and non-segmental vitiligo.

Prurigo Nodularis Treatment Market Size in Asia Pacific 2023 to 2033

The Asia Pacific prurigo nodularis treatment market size was calculated at USD 550 million in 2023 and is projected to expand around USD 840 million by 2033, poised to grow at a CAGR of 4.32% from 2024 to 2033.

Prurigo Nodularis Treatment Market Overview

Prurigo nodularis is a chronic skin condition characterized by intensely itchy nodules or bumps. The prurigo nodularis treatment market deals with pharmacies for treatment options, including phototherapy, systematic medications, antihistamines, capsaicin creams, immune modulators, and topical steroids. These treatments include topical medicines such as nonsteroids or corticosteroids, and anti-inflammatory medicines may be used to apply to itchy spots. Injectable medications like corticosteroids may be directly injected into the affected areas.

In cryotherapy, freezing temperatures are applied to the skin, which helps reduce nodules and itching. Topical medications have some benefits, such as easy application and removal, irritant effects, solvent properties, penetrability, and stability. This prurigo nodularis treatment is useful, especially in emergencies like during childbirth and allergic reactions. These factors help the growth of the market.

Prurigo Nodularis Treatment Market Growth Factors

• Prurigo nodularis treatment is used in chronic skin conditions, emergencies during childbirth, and allergic reactions.
• This treatment includes various types of medications, including subcutaneous and intramuscular injections, which are administered in larger or controlled amounts and help drugs remain in the body for a long time.
• The benefits of prurigo nodularis treatment medications are that they are helpful for fast-acting relief, which helps the growth of the prurigo nodularis treatment market.
• Systematic and topical therapies aimed at stopping the flattening of the skin lesions and itch-scratch cycle.
• This treatment reduces skin scratching and irritation; medications may directly reduce itchiness.
• This treatment also includes fragrance-free laundry detergent, moisturizers, itch-relieving ointments, and lotion, and the use of mild soaps and not-too-hot baths or showers. These help to the growth of the market.

Prurigo Nodularis Treatment Market Scope

Prurigo Nodularis Treatment Market Dynamics

Driver: Increased skin infection diseases

Rising skin infection diseases lead to the growth of the market. These skin infections occur due to microbes, bacteria, and other viruses that enter the body and start to multiply. A changed lifestyle is also the reason for infectious diseases.  Prurigo nodularis treatment helps to stop itching and can heal the skin. This treatment includes an emollient that is applied to the skin, and it can reduce scratching. This is also helpful for flattening and softening the patches and bumps. The use of intralesional or topical steroids helps to treat prurigo nodularis. The use of systematic immunosuppressives or phototherapy helps the treatment of prurigo nodularis and helps the growth of the prurigo nodularis treatment market.

Restraint: Side effects of prurigo nodularis treatment

Prurigo nodularis treatment has some challenges, including the severity of prurigo nodularis, comorbidities, patient age, quality of life, and some side effects. Patients may be frustrated by the lack of improvement.  By using the medications, neurological and gastrointestinal side effects are observed commonly. A large number of patients experience the adverse side effects of peripheral neuropathy. In severe and recalcitrant cases of prurigo nodularis, treatment shows some significant side effects, including hypercoagulability, neuropathy, fatigue, and teratogenicity.

The use of systematic antihistamines for prurigo nodularis treatment can cause some side effects, including arrhythmias, tachycardia, dysuria, constipation, dry mouth, impaired cognitive functions, hyperexcitability, and sedation. The use of some systematic immunosuppressives can cause adverse side effects, including transaminitis, gastrointestinal symptoms, and nausea. These side effects factors can restrict the growth of the prurigo nodularis treatment market.

Opportunity: Research and development

Prurigo nodularis treatment has some side effects, and to overcome these effects, the development of medications with no side effects is necessary. Investment in research and development is necessary to help the growth of the market. Use of the biological treatments for the prurigo nodularis. Use of dupilumab as a biological treatment in medications for prurigo nodularis. The development of new targeted therapeutics for prurigo nodularis and prevention from other conditions, such as CKD or tuberculosis, HIV, hepatitis C, and hepatitis B. In some cases, topical treatments or injections are not effective, and there is a need for advanced therapies. Advanced therapies can be developed to overcome prurigo nodularis. These factors help the growth of the prurigo nodularis treatment market.

Product Type Insights

The corticosteroids segment dominated the market in 2023. The corticosteroid is the first-line treatment for prurigo nodularis, and it is used in the form of injections. The corticosteroids are anti-inflammatory drugs that are used to reduce inflammation and may help to reduce itching, pain, and redness right away. Intralesional corticosteroids, normally triamcinolone acetonide treatment, are generally used for the treatment of nodularis. Its low concentration may be effective, but a high concentration is needed to treat the scarred pruriginous lesions. Topical corticosteroid is a mainstay for the prurigo nodularis treatment. It is highly effective in reducing itching and may help to take away nodules.

Corticosteroid is used in medical tape for coating, which can relieve itching. To prevent scratching, it serves as a protective barrier, and it helps in flattening bumps. These topical corticosteroids can be used for about two weeks. These factors help the growth of the corticosteroids segment and contribute to the growth of the prurigo nodularis treatment market.

The antihistamines segment is expected to grow the fastest during the forecast period. Antihistamines are of two types sedating antihistamines and nonsedating antihistamines. Sedating antihistamines are used at bedtime, and non-sedating antihistamines are used in the daytime, which helps to relieve the itching due to prurigo nodularis. In topical treatments, antihistamine medications are directly applied to the skin in the form of ointments or skin. Calamine lotion is commonly used for relief from itching, and it is an antihistamine or anti-itching medication. These factors help the growth of the antihistamine segment and contribute to the growth of the prurigo nodularis treatment market.

• In June 2023, to identify the presence of histamine that may be found in some fishes which lead to scombroid poisoning the two new assays were designed and launched by the Neogen Corporation. These histamines help to keep the body safe but sometimes they overreact and can lead to allergic reactions and are used as antihistamines.
• In January 2024, a third-generation antihistamine-based ‘less drowsy’ drug for allergic rhinitis Nose-R soft cap (fexofenadine) was launched by SK Chemicals.

Distribution Channel Type Insights

The retail pharmacies segment dominated the prurigo nodularis treatment market in 2023. Increasing prurigo nodularis diseases leads to demand for lotions, ointments, and many other medications that are related to the prurigo nodularis treatment. Retail pharmacies are easily accessible and provide medications and services to customers at affordable prices. These retail pharmacy services include medication therapy management and medication dispensing activities.  In retail pharmacy, when covered with the beneficiary filling a prescription, the retail pharmacy collects beneficiary coinsurance or copayment and distributes the drug from the checklist.

The retail pharmacy passes the copayments to the pharmacy benefit managers (PBM), who pay the pharmacy the cleared compensation. People benefit from health and wellness services that are available in retail pharmacies and have high brand loyalty and satisfaction levels. Retail pharmacies provide both generic and branded drugs. These factors help to the growth of the retail pharmacy segments and contribute to the growth of the market.

The online pharmacies segment is estimated to be the fastest-growing during the forecast period. Online pharmacies offer many benefits. Online pharmacies are easily accessible and convenient for online shopping for prescription medicines, with the individual advantage of prescriptions filled from a mobile device, laptop, or PC. Online pharmacy permits individuals to buy their medications discreetly at the door. Online pharmacies have the benefits of saving money and one-on-one consultations.

In the U.S., Canada, and the North American region, online pharmacies' growth is attributed to an increased number of Internet consumers and rising access to online and web-based services. These factors help the growth of the online pharmacy segment and contribute to the growth of the prurigo nodularis treatment market.

Prurigo Nodularis Treatment Market Recent Developments

• In February 2023, Pfizer’s supplemental new drug applications (NDA) for abrocitinib (CIBINQO) was announced by the United States (U.S.) Food and Drug Application (FDA) for the treatment of serious atopic dermatitis, refractory, skin clearance, itching, severity, and disease extent for the 12 to less than 18 years of age group.
• In October 2023, new positive pruritus data for VTAMA Cream from their essential phase 3 trials was announced by a clinical-stage biopharmaceutical company, Dermavant Sciences (tapinarof). This is for children as young as two years old, and 1% of adults suffer from atopic dermatitis. It is also important to reduce itching, burning, redness, and itching.
• In February 2024, the Food and Drug Administration (FDA) accepted Galderma’s BLA (biological license application) for Nemolizumab to treat atopic dermatitis and prurigo nodularis.

Prurigo Nodularis Treatment Market Companies

• Bayer AG
• Celgene Corporation
• Glaxo Smith Kline plc
• Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
• Johnson & Johnson Services Inc.
• Merk & Co. Inc
• Novartis AG
• Pfizer Inc
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company Inc
• VYNE Therapeutics Inc.

Segments Covered in the Report

By Product Type

• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa